EVIIVE gets CHF 150,000 from Venture Kick to develop precision diagnostics for immunotherapy treatment selection
In the pursuit of scientific advancement, the journey from theoretical research to tangible solutions is often fraught with challenges.
Published by
Venture Kick
Immunotherapy has revolutionized cancer care, but its success remains inconsistent: less than 50% of patients respond to treatment for many types of cancer, including melanoma and lung, head, and neck cancers. This is largely due to the lack of reliable predictive biomarkers, forcing doctors into a hit-or-miss approach that delays effective treatment, exposes patients to unnecessary side effects, and costs billions annually in wasted healthcare resources.
EVIIVE’s proprietary platform, IMPASS (Immune-Pathogenesis Surveillance System), leverages extracellular vesicle (EV) analysis and machine learning to identify highly dynamic and tissue-specific biomarkers in liquid biopsies. Unlike conventional diagnostic methods, EVIIVE’s technology provides actionable insights before treatment begins, enabling oncologists to select the right immunotherapy for each patient upfront. This approach improves outcomes, reduces healthcare costs, and enhances patient care.
EVIIVE aims to capitalize on the growing immunotherapy market, expected to exceed USD 120 billion by 2030 due to the rising demand for precision diagnostics. The company is focused on progressing clinical validation and building strategic partnerships to meet the needs of the evolving biopharma sector.
Founded in 2022, EVIIVE boasts a highly skilled team with deep expertise in medical technology. Co-founders Dr. Kevin Yim, CEO, and Prof. Dr. Richard Chahwan, CSO, alongside Clinical Advisors Prof. Dr. Reinhard Dummer and Dr. Sandeep Wontakal, bring years of experience in medical research, clinical practice, and scientific innovation. Business Advisor Dr. Dimitri Aubert complements the team with a strong background in strategic growth, positioning EVIIVE to lead advancements in precision medicine and sepsis diagnostics.
EVIIVE’s Co-Founders: CSO Richard Chahwan and CEO Kevin Yim
Securing Venture Kick Stage 3 is a crucial milestone for EVIIVE. Funding, mentorship, and network access have played a key role in advancing our technology toward clinical impact,” stated CEO Kevin Yim. “We're excited to bring precision diagnostics to immunotherapy patients worldwide.
